semaglutide and pancreatitis risk of pancreatic cancer associated with GLP-1 receptor agonist therapy What are the risks and

In our cohort of 48 array-CGH GBM cases, we observed one patient with a distinct amplification peak of PSPH (chr7: 5584627356155279), in which EGFR was not included

Energy Shifts That Signal Metabolic Slowdown Fatigue that wasn't there before often accompanies plateaus

In some embodiments, the viscosity modulating agent is poloxamer

After 72 weeks on the highest maintenance dose (15mg) people lost an average 22.5% of their starting weight

Keeping the bedroom comfortable and cool

GLP-1 Receptor Agonists and Other Drugs Heres everything you need to know about GLP-1 medications like Ozempic, including benefits, side effects, and how to navigate your options